Max Robotics — Global Service Robot Directory + US Certification

About

Dr. J.M.S. De Baaij is a leading urologic oncologist whose research focuses on refining surgical outcomes for prostate cancer, particularly through the optimization of lymph node dissection during robot-assisted radical prostatectomy. His work critically evaluates the balance between oncologic efficacy and surgical morbidity, demonstrating that extended pelvic lymph node dissection (e-PLND) is an independent risk factor for major complications—a finding with direct implications for surgical decision-making. In a landmark 2021 study (29 citations), Dr. De Baaij established preoperative PSMA-PET/CT as a powerful predictor of biochemical persistence and early recurrence following radical prostatectomy, enabling more accurate risk stratification and personalized treatment planning. His comparative analyses of extended versus super-extended PLND have provided granular data on lymph node yield, metastasis detection, and biochemical recurrence rates, helping to define the optimal extent of dissection. By systematically evaluating complication profiles alongside oncologic outcomes, Dr. De Baaij’s research bridges the gap between aggressive surgical staging and patient safety, offering evidence-based guidance for urologic surgeons. His work continues to shape contemporary prostate cancer surgery, balancing the imperative for accurate nodal staging against the imperative to minimize harm.